Viewing Study NCT06874933

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 3:05 AM
Ignite Modification Date: 2026-03-05 @ 5:06 PM
Study NCT ID: NCT06874933
Status: RECRUITING
Last Update Posted: 2025-08-12
First Post: 2025-03-10
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Neoadjuvant Chemotherapy in Combination With Anlotinib and Benmelstobart for HR+/HER2- Breast Cancer (NEOTORCH-BREAST03)
Sponsor: First Affiliated Hospital of Zhejiang University
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None HR+/HER2- Breast Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Breast cancer View
None Anlotinib and Benmelstobart View
None Adjuvant Chemotherapy View
None HR-positive HER2-negative View